GSEP
EBS icon

Golden State Equity Partners’s Emergent Biosolutions EBS Stock Holding History

Golden State Equity Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$41 – 731
2026
Q1 		$41 Buy
+5
New +$52 ﹤0.01% 1993

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Golden State Equity Partners's EBS Position: Q2 2026 in Review

Golden State Equity Partners sold out of Emergent Biosolutions (EBS) in Q2 2026, closing a stake of 5 shares — an estimated $41 sold.

Golden State Equity Partners first reported a position in EBS in Q1 2026 and held it in 1 quarter. The position peaked at $41 in Q1 2026. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Golden State Equity Partners reported no remaining Emergent Biosolutions position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 5 Emergent Biosolutions shares in Q2 2026, an estimated $41.
  • Golden State Equity Partners first reported a position in Emergent Biosolutions in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Emergent Biosolutions position peaked at $41 in Q1 2026.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.